Adam S. Grossman Buys 485,000 Shares of ADMA Biologics Inc (ADMA) Stock
ADMA Biologics Inc (NASDAQ:ADMA) insider Adam S. Grossman acquired 485,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were purchased at an average price of $2.15 per share, for a total transaction of $1,042,750.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
ADMA Biologics Inc (NASDAQ:ADMA) opened at $2.75 on Wednesday. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics Inc has a 1 year low of $2.01 and a 1 year high of $6.47.
A number of research analysts have weighed in on ADMA shares. ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Raymond James Financial, Inc. upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research report on Tuesday.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.